Ubs Group Ag I Mab Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in I Mab stock. As of the latest transaction made, Ubs Group Ag holds 318,546 shares of IMAB stock, worth $299,433. This represents 0.0% of its overall portfolio holdings.
Number of Shares
318,546
Previous 103,054
209.11%
Holding current value
$299,433
Previous $87,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding IMAB
# of Institutions
38Shares Held
13.8MCall Options Held
20KPut Options Held
13.3K-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$5.62 Million0.15% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$3.92 Million3.04% of portfolio
-
Sg Americas Securities, LLC822KShares$772,7180.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR484KShares$454,6280.39% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny363KShares$341,4080.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $78.1M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...